JWH-363

JWH-363 is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB₁ and CB₂ receptors, with a moderate selectivity for the latter. JWH-363 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB₁ receptor.

Legality

In the United States JWH-363 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-363.
In Canada, JWH-363 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled [Drugs and Substances Act].
In the United Kingdom, JWH-363 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of [Drugs Act 1971].